iwNHL 2020 Highlights

As the iwNHL’s official media partner, the Video Journal of Hematological Oncology (VJHemOnc) will cover the iwNHL 2020 meeting to facilitate roundtable discussions and interviews with experts for the benefit of clinicians and researchers in the field of NHL. Highlights from the iwNHL 2020 meeting can be viewed here.

Early-stage unfavorable cHL

Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany


Pier Luigi Zinzani, MD, PhD, University of Bologna, Bologna

Hodgkin’s Lymphoma in the era of targeted therapy

Peter Johnson, MB BChir, MD, MRCP, FRCP, University of Southampton, Southampton, UK

Crosstalk between lymphocytes and their microenvironment

Jan A. Burger, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX

CBT in specific lymphoma subtypes

Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI

Antibody Drug Conjugates

Laurie Sehn

CD20 / CD3 bispecific antibodies: How to choose?

Martin Hutchings, MD, PhD, The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen

Oral PI3K delta (δ) inhibitors in lymphoma

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

Novel BTK inhibitors: how to choose?

Tom Witzig, MD, Mayo Clinic Rochester, Rochester, MN

SINE inhibitors: Selinexor

John Kuruvilla, MD, FRCPC, The Princess Margaret Cancer Centre, Toronto, ON

Tafasitamab (MOR208) in DLBCL

Gilles Salles, MD, PhD, South Lyon Hospital, Lyon, France

CD19-CAR-T cells

Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA

CD30, CD5 and/or 7 CAR-T cells

Cath Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC

T cell-engaging therapies – BiTEs and beyond

Stephen Gottschalk, MD, St. Jude Children’s Research Hospital, Memphis, TN

© 2014 - 2021 World Health Communications Ltd